ARTICLE | Company News

State Medicaid group chooses Viekira Pak

January 29, 2015 1:39 AM UTC

Missouri's Medicaid agency said it will make Viekira Pak from AbbVie Inc. (NYSE:ABBV) its preferred regimen to treat HCV in exchange for undisclosed rebates. Missouri is part of a consortium of 24 states plus the District of Columbia that negotiated a rebate on Viekira.

The AbbVie regimen will replace Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as the preferred treatment for HCV genotype 1 patients. Missouri's Department of Social Services (DSS) said Sovaldi will still be available to the estimated 15-20% of patients who cannot tolerate Viekira. ...